Clinical trial
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified…
NCT00486954 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00486954 |
|---|---|
| Title | Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer |
| Official title | A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Gastrointestinal Tract |
| Intervention type | Drug |
| Interventions | Lapatinib, Paclitaxel |
| Enrollment | 273 |
| Start date | Jul 1, 2007 |
| Primary completion | Jan 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Jun 15, 2007 |
| Last update posted | Jun 20, 2013 |
| Countries | China, Japan, South Korea, Taiwan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: